When we challenge the complexity of cases, we advance ways to identify heart failure events.
Logo When we challenge the complexity of cases, we advance ways to identify heart failure events.
Healthcare Professionals / Heart Failure

Heart Failure

We’re dedicated to developing heart failure innovations that may help with early detection of worsening heart failure, enhance clinical efficiencies and improve patients’ lives. From devices powered by the industry’s longest battery life1-9 to a heart failure diagnostic that helps you triage your patients, explore our pioneering technologies that give you the power to do things that once seemed out of reach.




electrophysiology products

Insights That Keep You a Beat Ahead

HeartLogic is the only FDA-approved heart failure diagnostic that combines data from multiple sensors into one composite index and can help you predict signs of worsening heart failure weeks in advance. Making it your recommendation could make a big difference in the lives of your patients.
clinical support
electrophysiology products

The Right Information at the Right Time

HeartLogic is validated to provide weeks of advance notice for detecting early signs of worsening heart failure via a proactive alert in LATITUDE™ NXT.10 HeartLogic changes the landscape by shifting heart failure patient care from reactive treatment to proactive management.


electrophysiology products

Heart Failure Management Products

Discover our portfolio of products designed to help you diagnose and treat heart failure, including automatic remote monitoring technologies and the longest lasting CRT-Ds in the world.


Device longevity

Device Longevity

CRT-Ds powered with EnduraLife Battery Technology are labeled for up to 13.3 years, even when MultiSite Pacing is turned on and let you remotely monitor patients without compromising longevity.11
Device longevity

MRI Compatibility12

Boston Scientific devices with ImageReady MR Conditional Systems allow your heart failure patients to safely undergo 1.5T or 3T full-body MRI scans.

We're Here To Help

request a rep

Request A Sales Rep

Have a sales rep contact you to discuss how our portfolio of products can help you achieve better patient outcomes.

contact support

Get Support

Find contact information, technical support, ordering information and other resources for heart failure clinicians..

request a rep

HeartLogic Training

Find an interactive CE course, training videos, study guides and other tools to help you improve clinic workflows and implement HeartLogic in your practice.

contact support

Key Resources

Case studies

Case Studies

See how HeartLogic is making a difference in real-world cases.

Product Performance Center

Product Performance Center

Get detailed product performance and survival probability data.

Trugevity Calculator

Trugevity Calculator

Calculate how far you and your patients can go with EnduraLife.



Canadian Class Actions

View the Notice of Certification in Lambert, et al. v. Guidant Corp. Français | English


1) Haarbo J, Hjortshoj S, Johansen J, Jorgensen O, Nielsen J, Petersen H. Device Longevity in Cardiac Resynchronization Therapy Implantable Cardioverter Defibrillators Differs Between Manufacturers: Data from the Danish ICD Registry. Presented at HRS 2014. http://ondemand.hrsonline.org/common/presentation-detail.aspx/15/35/1241/9000. Boston Scientific = 136 patients, Medtronic = 651 patients, St. Jude Medical = 1,587 patients, Bitronik = 369 patients. Time to exchange of the device because of battery depletion or device failure recorded in the Danish ICD Registry was the endpoint. The four-year survival rate for devices in the Danish Registry study was 81.1% for Medtronic and 95.7% for Boston Scientific (P<0.01).

2) J. Williams, R. Stevenson. Contemporary cardiac resynchronization implantable cardioverter defibrillator battery longevity in a community hospital heart failure cohort. Presented at HFSA 2014. http://www.onlinejcf.com/article/. S1071-9164(14)00389-3/fulltext. Boston Scientific = 53 patients, Medtronic = 28 patients, St. Jude Medical = 10 patients. Four-year survival rate calculated using device replacements for battery depletion as indicated by ERI.

3) Ellis CR, Dickerman DI, Orton JM, Hassan S, Good EG, Okabe T, Andruilli JA, Quan KJ, Greenspon AJ. Ampere Hour as a Predictor of Cardiac Resynchronization Defibrillator Pulse Generator Battery Longevity: A Multicenter Study. PACE 2016 doi: 10.1111/pace.12831 first published online 11-MAR-2016. The five major institutions performing the study include, at Vanderbilt University, Henry Ford Hospital, University of Michigan, Thomas Jefferson University, Cooper Health System, North Ohio Heart Center. Boston Scientific = 322 patients, Medtronic = 794 patients, St. Jude Medical = 186 patients. Five-year survival rate calculated using device replacements for battery depletion as indicated by ERI.

4) Landolina M, Curnis A, Morani G, Vado A, Ammendola E, D’onofrio A, Stabile G, Crosato M, Petracci B, Ceriotti C, Bontempi L, Morosato M, Ballari GP, Gasparini M. Longevity of implant Cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer. Europace2015;17:1251-58. doi:10.1093/eurospace/euv109. First published online: May 14, 2015. Medtronic = 532 patients, Boston Scientific = 291 patients, St. Jude Medical = 106 patients, Biotronik = 20 patients, Sorin = 69. Five-year survival rate of latest marketed devices (between 2006 to 2010) calculated using device replacements for battery depletion as indicated by ERI.

5) Zanon F, Martignani C, Ammendola E, Menardi E, Narducci ML, De Filippo P, Santamaria M, Campana A, Stabile G, Potenza DR, Pastore G, Iori M, La Rosa C, and Biffi M. Device Longevity in a Contemporary Cohort of ICD/CRT-D Patients Undergoing Device Replacement. Doi:10.1111/jce.12990, First published online 20-APR-2016. Comparison of device longevity by Kaplan-Meier curves of CRT-D systems extracted between March 2013 and May 2015. Medtronic = 195 patients, Boston Scientific = 157 patients, St. Jude = 72, Biotronik = 9.

6) Provided by Dr. Ernest Lau on 04/29/15 in support of Lau E, Wilson C, Ashfield K, McNair W, McEneany D, Roberts M, Large Capacity LiMnO2 Batteries Extended CRTD Longevity in Clinical Use Compared to Smaller Capacity LiSVO Batteries Over 6 Years. Presented at HRS 2015. Medtronic = 62 patients, Boston Scientific = 27 patients, St. Jude = 66 patients. Five-year survival rate calculated using device replacements for battery depletion as indicated by ERI.

7) von Gunten S, Schaer BA, Yap SC, Szili-Torok T, Kühne M, Sticherling C, Osswald S, Theuns DA. Longevity of implantable cardioverter defibrillators: a comparison among manufacturers and over time. Europace. 2015 Nov 25; . Epub 2015 Nov 25. Total patients = 3436.

8) Alam MB, Munir MB, Rattan R, Adelstein E, Jain S, Saba S. Battery longevity from cardiac resynchronization therapy defibrillators: differences between manufacturers and discrepancies with published product performance reports. Europace 016;doi:10.1093/europace/euw044. First published online: 22-MAR-2016. Kaplan Meier curves depicting survival of CRT devices free from battery depletion by device manufacturer. Battery Longevity in Cardiac Medtronic = 416 patients, Boston Scientific = 173 patients, St. Jude Medical = 57patients. Previously evaluated these patients at a four-year survival rate calculated using device replacements for battery depletion as indicated by ERI. 2014; Europace (2014) 16,246-51.

9) Shabanna Din, Shabanna, Mcgee, Rao, Archana, Wright, Jay D. Longevity of implantable cardioverter defibrillators: The impact of device manufacturer and device type on device longevity were assessed. Europace. 2015 Nov 25; . Epub 2015 Nov 25. Total patients = 3436. Cardiostim Abstract 2016. Total patients = 1489.

10) Boehmer, J et al., JACC-HF, 2017;5(3),2 1 6 – 2 5

11) Assumes: 2.0V RA, LV-only, 2.0V LVa, 2.0V LVb, 700Ω, No LATITUDE, No Respiratory Rate Sensor, No Heart Failure Sensor Suite.

12) When conditions of use are met.